The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow P 2Y 12 assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation

Kyounghoon Lee, Seung Whan Lee, Jun Won Lee, Seong Yoon Kim, Young Jin Youn, Min Soo Ahn, Jang Young Kim, Byung Su Yoo, Junghan Yoon, Kyung Hoon Choe

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background and Objectives: Clopidogrel resistance or low-responsiveness may be associated with recurrent atherothrombotic events after drug-eluting stent (DES) implantation. We prospectively evaluated the association between clopidogrel resistance assessed by the Verifynow™ P 2Y 12 assay (Accumetrics, San Diego, CA, USA) and stent thrombosis (ST) or cardiac death (CD) in patients with acute coronary syndrome (ACS) within 6 months after DES implantation. Subjects and Methods: We enrolled 237 consecutive patients (160 males, 65.2 ± 10.3 years) with ACS who received a DES implantation. The composite endpoint was defined to CD or ST by Academic Research Consortium definitions within 6 months post-implantation. Clopidogrel resistance was defined as <20% inhibition of the P 2Y 12 receptor. Results: Baseline demographic characteristics were similar between 142 normal individuals and 95 clopidogrel resistant patients. CD occurred in one case (0.7%) in the normal group and two cases (2.13%) in the resistant group (p=0.344). There was no episode of ST in the normal group and four episodes in the resistant group (4.2%, four definite ST) (p=0.035). Univariate logistic regression revealed an adjusted odds ratio (OR) for composite end point of CD or ST of 9.646 {95% confidence interval (CI) 1.139-81.679}, and multivariate logistic regression for composite end point revealed an OR of 12.074 (95% CI 1.205-120.992). Conclusion: Clopidogrel low-responsiveness assessed by the Verifynow™ P 2Y 12 assay is an independent predictor of ST and composite end point of ST or CD in patients with ACS within 6 months after DES implantation.

Original languageEnglish
Pages (from-to)512-518
Number of pages7
JournalKorean Circulation Journal
Volume39
Issue number12
DOIs
Publication statusPublished - 2009 Dec 1

Fingerprint

clopidogrel
Drug-Eluting Stents
Acute Coronary Syndrome
Stents
Thrombosis
Logistic Models
Odds Ratio
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{fa6c1f09093b4f27b009d88cdb64a3d6,
title = "The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow P 2Y 12 assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation",
abstract = "Background and Objectives: Clopidogrel resistance or low-responsiveness may be associated with recurrent atherothrombotic events after drug-eluting stent (DES) implantation. We prospectively evaluated the association between clopidogrel resistance assessed by the Verifynow™ P 2Y 12 assay (Accumetrics, San Diego, CA, USA) and stent thrombosis (ST) or cardiac death (CD) in patients with acute coronary syndrome (ACS) within 6 months after DES implantation. Subjects and Methods: We enrolled 237 consecutive patients (160 males, 65.2 ± 10.3 years) with ACS who received a DES implantation. The composite endpoint was defined to CD or ST by Academic Research Consortium definitions within 6 months post-implantation. Clopidogrel resistance was defined as <20{\%} inhibition of the P 2Y 12 receptor. Results: Baseline demographic characteristics were similar between 142 normal individuals and 95 clopidogrel resistant patients. CD occurred in one case (0.7{\%}) in the normal group and two cases (2.13{\%}) in the resistant group (p=0.344). There was no episode of ST in the normal group and four episodes in the resistant group (4.2{\%}, four definite ST) (p=0.035). Univariate logistic regression revealed an adjusted odds ratio (OR) for composite end point of CD or ST of 9.646 {95{\%} confidence interval (CI) 1.139-81.679}, and multivariate logistic regression for composite end point revealed an OR of 12.074 (95{\%} CI 1.205-120.992). Conclusion: Clopidogrel low-responsiveness assessed by the Verifynow™ P 2Y 12 assay is an independent predictor of ST and composite end point of ST or CD in patients with ACS within 6 months after DES implantation.",
author = "Kyounghoon Lee and Lee, {Seung Whan} and Lee, {Jun Won} and Kim, {Seong Yoon} and Youn, {Young Jin} and Ahn, {Min Soo} and Kim, {Jang Young} and Yoo, {Byung Su} and Junghan Yoon and Choe, {Kyung Hoon}",
year = "2009",
month = "12",
day = "1",
doi = "10.4070/kcj.2009.39.12.512",
language = "English",
volume = "39",
pages = "512--518",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "12",

}

TY - JOUR

T1 - The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow P 2Y 12 assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation

AU - Lee, Kyounghoon

AU - Lee, Seung Whan

AU - Lee, Jun Won

AU - Kim, Seong Yoon

AU - Youn, Young Jin

AU - Ahn, Min Soo

AU - Kim, Jang Young

AU - Yoo, Byung Su

AU - Yoon, Junghan

AU - Choe, Kyung Hoon

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background and Objectives: Clopidogrel resistance or low-responsiveness may be associated with recurrent atherothrombotic events after drug-eluting stent (DES) implantation. We prospectively evaluated the association between clopidogrel resistance assessed by the Verifynow™ P 2Y 12 assay (Accumetrics, San Diego, CA, USA) and stent thrombosis (ST) or cardiac death (CD) in patients with acute coronary syndrome (ACS) within 6 months after DES implantation. Subjects and Methods: We enrolled 237 consecutive patients (160 males, 65.2 ± 10.3 years) with ACS who received a DES implantation. The composite endpoint was defined to CD or ST by Academic Research Consortium definitions within 6 months post-implantation. Clopidogrel resistance was defined as <20% inhibition of the P 2Y 12 receptor. Results: Baseline demographic characteristics were similar between 142 normal individuals and 95 clopidogrel resistant patients. CD occurred in one case (0.7%) in the normal group and two cases (2.13%) in the resistant group (p=0.344). There was no episode of ST in the normal group and four episodes in the resistant group (4.2%, four definite ST) (p=0.035). Univariate logistic regression revealed an adjusted odds ratio (OR) for composite end point of CD or ST of 9.646 {95% confidence interval (CI) 1.139-81.679}, and multivariate logistic regression for composite end point revealed an OR of 12.074 (95% CI 1.205-120.992). Conclusion: Clopidogrel low-responsiveness assessed by the Verifynow™ P 2Y 12 assay is an independent predictor of ST and composite end point of ST or CD in patients with ACS within 6 months after DES implantation.

AB - Background and Objectives: Clopidogrel resistance or low-responsiveness may be associated with recurrent atherothrombotic events after drug-eluting stent (DES) implantation. We prospectively evaluated the association between clopidogrel resistance assessed by the Verifynow™ P 2Y 12 assay (Accumetrics, San Diego, CA, USA) and stent thrombosis (ST) or cardiac death (CD) in patients with acute coronary syndrome (ACS) within 6 months after DES implantation. Subjects and Methods: We enrolled 237 consecutive patients (160 males, 65.2 ± 10.3 years) with ACS who received a DES implantation. The composite endpoint was defined to CD or ST by Academic Research Consortium definitions within 6 months post-implantation. Clopidogrel resistance was defined as <20% inhibition of the P 2Y 12 receptor. Results: Baseline demographic characteristics were similar between 142 normal individuals and 95 clopidogrel resistant patients. CD occurred in one case (0.7%) in the normal group and two cases (2.13%) in the resistant group (p=0.344). There was no episode of ST in the normal group and four episodes in the resistant group (4.2%, four definite ST) (p=0.035). Univariate logistic regression revealed an adjusted odds ratio (OR) for composite end point of CD or ST of 9.646 {95% confidence interval (CI) 1.139-81.679}, and multivariate logistic regression for composite end point revealed an OR of 12.074 (95% CI 1.205-120.992). Conclusion: Clopidogrel low-responsiveness assessed by the Verifynow™ P 2Y 12 assay is an independent predictor of ST and composite end point of ST or CD in patients with ACS within 6 months after DES implantation.

UR - http://www.scopus.com/inward/record.url?scp=75149167046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149167046&partnerID=8YFLogxK

U2 - 10.4070/kcj.2009.39.12.512

DO - 10.4070/kcj.2009.39.12.512

M3 - Article

C2 - 20049136

AN - SCOPUS:75149167046

VL - 39

SP - 512

EP - 518

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 12

ER -